3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Prostatic Neoplasms
9
Ovarian Neoplasms
8
Breast Neoplasms
7
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasm Epithelial
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
olaparib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Solid Tumor, Adult
×
olaparib
×
Clear all
NCT04972110
2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2
Terminated
156 enrolled
19 charts